**ASX Announcement**

4 June 2024 (Melbourne, Australia)

**Optiscan Imaging Ltd (ASX:OIL)**

**Optiscan Reveals InVue™ Imaging Device for Precision Surgery**

This next-gen imaging device tailors Optiscan’s patented technology to the surgical market, and can be used in a wide range of clinical settings, including cancer diagnosis and treatment.

**Highlights**

- Optiscan reveals InVue™ next-gen microscopic medical imaging device for precision surgery.
- InVue™ expands Optiscan’s product portfolio into the surgical application market, representing a significant step forward in realising the Company’s strategic goals.
- InVue™ can be used in a variety of clinical settings, most notably in cancer diagnosis and treatment.
- InVue™ is designed to put digital pathology directly in the hands of surgeons as they operate, to enable on-the-spot decision making and treatment adjustments.

**Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘The Company’) is pleased to announce the reveal of its ground-breaking new microscopic medical imaging device, InVue™, which is designed to enable precision surgery by putting real-time digital pathology access directly into the hands of surgeons.** The device has been designed and manufactured in Melbourne by Optiscan in partnership with Sydney and Melbourne-based industrial design firm Design + Industry.

**InVue™ is a step-change in the ongoing evolution of pathology**

The InVue™ device reveal is tangible evidence that Optiscan is successfully expanding its product portfolio, in the process delivering a core component of the Company’s growth strategy. Leveraging Optiscan’s patented technology, the device is designed to be used by surgeons to gain immediate pathology insights in the operating theatre, to enable on-the-spot decision making, treatment adjustments and precision surgery.

The quicker delivery of such insights represents a significant step in the evolution of pathology, which has historically been conducted within dedicated pathology laboratories using analogue approaches, separate to the operating theatre. The current pathology workflow is time-consuming, requires multiple procedures, and provides surgeons with results after significant time delays.

The InVue™ device has been designed for ease of use in various clinical settings such as cancer diagnosis and treatment. It will deliver surgeons real-time microscopic imaging and pathology detail, which will assist them to improve the accuracy of their diagnoses and reduce the need for multiple diagnostic procedures and repeat surgeries.
Importantly, the device is expected to do more than just enable more precise treatment. By delivering improving accuracy and speed of treatment, the device should also help lower healthcare costs and improve patient outcomes.

The InVue™ has a spatial resolution of 0.55µ and is more than 1000x more powerful than traditional CT and MRI scanners with a typical resolution of 0.5-1mm. The InVue™ is DICOM-compliant and PACS-enabled, and designed to integrate with Optiscan’s cloud-based telepathology platform which is expected to be revealed in 2025, and which will surgeons and pathologists to collaborate on surgical cases in real-time from anywhere in the world.

Optiscan CEO and Managing Director, Dr Camile Farah, said: “Getting our next-gen InVue™ microscopic medical imaging device to the reveal stage is a real credit to the hard work of the entire Optiscan team. The reveal is much more than just a significant milestone in the Company’s growth strategy. It paves the way for a significant evolution of digital pathology and precision surgery. InVue™ will bring digital pathology insights into the operating theatre and directly into the hands of surgeons. The end-result will be enhanced speed and accuracy of treatment, which should in turn deliver improved patient outcomes.”

“We are particularly excited by what the InVue™, which tailors our patented technology to the surgical market, will mean for the future treatment and diagnosis of cancer patients. It will facilitate a dramatic step forward in the way cancer can be diagnosed and treated with unprecedented accuracy and precision. Our first intended use of InVue™ is for breast cancer surgery and margin determination. This form of cancer is the most commonly diagnosed cancer amongst women in Australia, with over 20,000 Australians diagnosed each year. In the US, this number is as high as 300,000 per year, which is an important and large addressable market.”
Dr Farah adds: “The potential benefits flowing from the InVue™ cannot be over-estimated. Diagnostic pathology is such a critical component in the surgical treatment of cancer, and for so long it has been disconnected from this process. InVue™ brings pathology and surgery together in the operating theatre to enhance the capabilities of both, and ultimately facilitate faster and more accurate patient care.”

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
T: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
The Capital Network
Julia Maguire
T: +61 2 8999 3699
E: julia@thecapitalnetwork.com.au

About Optiscan
Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, in-vivo digital imaging at the single-cell level. We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures. Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X or Instagram.

Disclaimer
All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate’, ‘believe’, ‘could’, ‘estimate’, ‘expect’, ‘future’, ‘intend’, ‘may’, ‘opportunity’, ‘plan’, ‘potential’, ‘project’, ‘seek’, ‘will’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.